Quick Answer
Cabaletta Bio, Inc. reported Stockholders Equity of $112.05 million for the year ending 2025.
- Cabaletta Bio, Inc. showed a decrease of -26.4% in Stockholders Equity from 2024 to 2025.
- This data is from Cabaletta Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$1.14 million | Q3 2018: -$10.22 million | Q1 2019: -$19.05 million | Q2 2019: -$21.99 million | Q3 2019: -$26.08 million | Q1 2020: $131.71 million | Q2 2020: $124.64 million | Q3 2020: $117.51 million | Q1 2021: $103.31 million | Q2 2021: $101.33 million | Q3 2021: $116.62 million | Q1 2022: $106.72 million | Q2 2022: $95.53 million | Q3 2022: $85.87 million | Q1 2023: $91.65 million | Q2 2023: $174.14 million | Q3 2023: $160.92 million | Q1 2024: $221.72 million | Q2 2024: $199.52 million | Q3 2024: $174.24 million | Q1 2025: $121.55 million | Q2 2025: $178.48 million | Q3 2025: $139.47 million.
- Over the full 9 years of available data (2017 to 2025), Cabaletta Bio, Inc.'s Stockholders Equity has grown by 45,100.4%.
- Historical annual values: Fiscal year 2025: $112.05 million | Fiscal year 2024: $152.34 million | Fiscal year 2023: $236.20 million | Fiscal year 2022: $104.52 million | Fiscal year 2021: $117.96 million | Fiscal year 2020: $109.54 million | Fiscal year 2019: $138.32 million | Fiscal year 2018: -$10.69 million | Fiscal year 2017: -$249.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: